Hematology/Oncology

Top Story

High-risk gastric cancer drug enters phase 2 testing

July 20, 2017

Cancer Prevention Pharmaceuticals Inc. launched a phase 2 clinical trial to assess CPP-1X, a therapy for the treatment of gastric cancer previously given orphan drug designation from the FDA, in patients with precancerous gastric lesions, according to a press release.

“Currently, there are no agents for the prevention of gastric cancer in patients with precancerous conditions of the stomach,” Keith T. Wilson, MD, Thomas F. Frist Sr. Chair in medicine and professor of medicine in the division of gastroenterology, hepatology and nutrition at Vanderbilt University Medical Center, said in the release.

FDA News

FDA grants orphan drug designation to gilteritinib for acute myeloid leukemia

July 20, 2017
The FDA granted orphan drug designation to gilteritinib for the treatment of acute myeloid leukemia, according to the agent’s manufacturer. Gilteritinib (ASP2215…
In the Journals Plus

Autologous stem cell transplantation improves outcomes in refractory myeloma

July 20, 2017
High-dose therapy with autologous hematopoietic stem cell transplantation appeared safe and effective among patients with refractory multiple myeloma, according to a…
NewsMeeting News

Maintenance pembrolizumab benefits certain patients with small cell lung cancer

July 19, 2017
CHICAGO – Improvements in OS, but not PFS, indicate that maintenance treatment with pembrolizumab may benefit a subset of patients with small cell lung cancer, and…
Meeting NewsVideo

VIDEO: Genomic risk system may help treat prostate cancer

July 19, 2017
CHICAGO — The use of a genomic classifier in combination with clinicopathologic variables may provide a valuable prognostic system for distant metastases and…
More News Headlines »
CME

Hot Topics in Metastatic Breast Cancer Management: Clinical Advances with CDK4/6 Inhibitors

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

While the mortality rates for advanced or metastatic breast cancer (MBC) have steadily decreased, in part due to…
More »
Video
Meeting News

VIDEO: Pembrolizumab may improve response to CAR T-cell therapy in children with ALL

June 20, 2017
More »
Resource Centers
Biosimilars in the US

Biosimilars in the US

CME

The Patient with Invasive Breast Cancer

No commercial support for this activity.

This CME activity will focus on the diagnosis and management of patients with invasive breast cancer.
More »
Current Issues
View the Current Issue
HemOnc Today
Advertisement
Advertisement